Who Exports Atovaquone from India — 17 Suppliers Behind a $990.7M Market
India's atovaquone export market is supplied by 17 active exporters who collectively shipped $990.7M across 437 shipments. MYLAN LABORATORIES LIMITED leads with a 94.3% market share, followed by GLENMARK PHARMACEUTICALS LIMITED and HETERO LABS LIMITED. The top 5 suppliers together control 100.0% of total export value, reflecting a concentrated market structure.
Top Atovaquone Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading atovaquone exporter from India, holding a 94.3% share of the $990.7M market across 437 shipments from 17 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, GLENMARK PHARMACEUTICALS LIMITED, HETERO LABS LIMITED, LUPIN LIMITED, GLENMARK PHARMACEUTICALS LTD — collectively control 100.0% of total export value, indicating a highly concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (94.3%), GLENMARK PHARMACEUTICALS LIMITED (2.8%), HETERO LABS LIMITED (2.2%), LUPIN LIMITED (0.5%), GLENMARK PHARMACEUTICALS LTD (0.1%).
Top Atovaquone Exporters from India
Ranked by export value · 17 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED ATOVAQUONE ORAL SOLUTIONATOVAQUONE 750MG/5ML ORAL SOLUTIONATOVAQUONE LIQUID SYRUP | $934.1M | 5 | 94.3% |
| 2 | GLENMARK PHARMACEUTICALS LIMITED ATOVAQUONE ORAL SOLUTIONATOVAQUONE 750MG/5ML ORAL SOLUTIONATOVAQUONE LIQUID SYRUP | $28.1M | 11 | 2.8% |
| 3 | HETERO LABS LIMITED ATOVAQUONE ORAL SOLUTIONATOVAQUONE 750MG/5ML ORAL SOLUTIONATOVAQUONE LIQUID SYRUP | $22.1M | 4 | 2.2% |
| 4 | LUPIN LIMITED ATOVAQUONE ORAL SOLUTIONATOVAQUONE 750MG/5ML ORAL SOLUTIONATOVAQUONE LIQUID SYRUP | $5.3M | 1 | 0.5% |
| 5 | GLENMARK PHARMACEUTICALS LTD ATOVAQUONE ORAL SOLUTIONATOVAQUONE 750MG/5ML ORAL SOLUTIONATOVAQUONE LIQUID SYRUP | $797.2K | 3 | 0.1% |
| 6 | YASHICA PHARMACEUTICALS PRIVATE LIMITED YASHIRONE TABLETS (ATOVAQUONE 250MG + PRATOVAQUONE/PROGUANIL 250/100MG TABLETSATOVAQUONE AND PROGUANIL HCL | $189.7K | 4 | 0.0% |
| 7 | LIVEALTH BIOPHARMA PRIVATE LIMITED | $45.6K | 2 | 0.0% |
| 8 | KALINDI OVERSEAS ATOVAQUONE ORAL SOLUTIONATOVAQUONE 750MG/5ML ORAL SOLUTIONATOVAQUONE LIQUID SYRUP | $38.6K | 3 | 0.0% |
| 9 | 3S PHARMACEUTICALS INDIA PRIVATE LIMITED MALAGLEN TABLETS 1X12'S UAEATOVAQUONE PROGUANIL TABS 250/100MG 24'S,ATOVAQUONE & PROGUANIL HYDROCHLORIDE TABLETS | $26.9K | 2 | 0.0% |
| 10 | P.B.P ENTERPRISES PRIVATE LIMITED | $1.8K | 1 | 0.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Atovaquone exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| MYLAN LABORATORIES LIMITED | Approved | Yes, valid until Dec | Not Listed | Not verified | FDA approval and WHO-GMP certification valid through December 2023. |
| GLENMARK PHARMACEUTICALS LIMITED | Warning Letter, July 2025 | Not Listed | Not Listed | Not verified | FDA issued a warning letter in July 2025 for the Madhya Pradesh facility. |
| HETERO LABS LIMITED | Approved | Yes | Yes | Not verified | Hetero Labs holds FDA approval, WHO-GMP, and EU GMP certifications. |
| LUPIN LIMITED | Approved | Yes | Yes | Not verified | Lupin Limited maintains FDA approval, WHO-GMP, and EU GMP certifications. |
| YASHICA PHARMACEUTICALS PRIVATE LIMITED | Not Listed | Yes | Not Listed | Not verified | WHO-GMP certified; no FDA listing found. |
| LIVEALTH BIOPHARMA PRIVATE LIMITED | Not Listed | Yes | Not Listed | Not verified | WHO-GMP certified; no FDA listing found. |
| KALINDI OVERSEAS | Not Listed | Yes | Not Listed | Not verified | WHO-GMP certified; no FDA listing found. |
| 3S PHARMACEUTICALS INDIA PRIVATE LIMITED | Not Listed | Yes | Not Listed | Not verified | WHO-GMP certified; no FDA listing found. |
| P.B.P ENTERPRISES PRIVATE LIMITED | Not Listed | Yes | Not Listed | Not verified | WHO-GMP certified; no FDA listing found. |
TransData Nexus reviewed the regulatory standing of 9 leading Atovaquone exporters from India. 3 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 2 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Atovaquone sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," hosts over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. The city is renowned for its production of Active Pharmaceutical Ingredients (APIs) and has a robust infrastructure supporting pharmaceutical manufacturing. Notably, Hetero Labs Limited, one of the top exporters of Atovaquone, is headquartered in Hyderabad, underscoring the city's pivotal role in the production and export of this antiprotozoal medication.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a significant hub for pharmaceutical formulations, contributing nearly 28% of India's pharmaceutical production. This region is home to leading companies such as Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. The presence of manufacturers like Shreeji Pharma International in Vadodara, which specializes in Atovaquone production, highlights the area's capacity for both API and finished dosage form manufacturing.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a crucial export gateway for India's pharmaceutical industry. With a concentration of pharmaceutical companies and proximity to major ports, this region facilitates efficient export operations. Companies like NGL Fine-Chem Ltd., based in Mumbai, are involved in the production of Atovaquone, leveraging the region's strategic advantages for global distribution.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, housing over 1,000 units and contributing significantly to India's pharmaceutical output. The region's growth has been bolstered by favorable government policies and tax incentives, attracting numerous pharmaceutical companies to establish manufacturing facilities.
5Sourcing Recommendations
- Diversify Supplier Base: While MYLAN LABORATORIES LIMITED dominates Atovaquone exports, consider engaging with other manufacturers like Hetero Labs Limited and Shreeji Pharma International to mitigate supply chain risks.
- Leverage Regional Strengths: Utilize Hyderabad's expertise in API production and the Ahmedabad-Vadodara region's capabilities in formulations to optimize sourcing strategies.
- Optimize Logistics: Capitalize on the Mumbai-Thane-Raigad region's proximity to major ports for efficient export operations.
- Explore Incentive Zones: Assess the benefits of manufacturing in tax incentive zones like Baddi-Nalagarh to reduce production costs.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Atovaquone exporters from India
Viatris Inc. (formerly Mylan Laboratories Limited) — Viatris divests multiple business units for $3.6 billion
In October 2023, Viatris reached agreements to divest nearly all of its over-the-counter (OTC) business, women's healthcare business, and its India-based active pharmaceutical ingredients (API) business for approximately $3.6 billion. - IMPACT: This divestiture may lead to a strategic realignment, potentially affecting Viatris's focus on Atovaquone production and export capabilities.
Impact: This divestiture may lead to a strategic realignment, potentially affecting Viatris's focus on Atovaquone production and export capabilities.
Viatris Inc. (formerly Mylan Laboratories Limited) — FDA issues warning letter and import alert to Viatris's Indore facility
In late December 2024, the U.S. FDA issued a warning letter and an import alert concerning Viatris's manufacturing facility in Indore, India. The alert affects 11 actively distributed products, which will no longer be accepted into the U.S. until the issues are resolved. The violations cited include subpar quality control and improper management of manufacturing defects. - IMPACT: This regulatory action could disrupt Viatris's Atovaquone exports to the U.S., potentially impacting supply chains and market availability.
Impact: This regulatory action could disrupt Viatris's Atovaquone exports to the U.S., potentially impacting supply chains and market availability.
Glenmark Pharmaceuticals Limited — Glenmark sells 75% stake in Glenmark Life Sciences to Nirma Limited
In July 2024, Glenmark Pharmaceuticals completed the divestment of a 75% stake in Glenmark Life Sciences to Nirma Limited for approximately ₹5,651 crore. This strategic move aimed to reduce debt and refocus on Glenmark's core innovative pipeline. - IMPACT: The divestiture may influence Glenmark's API production strategies, potentially affecting Atovaquone supply and export dynamics.
Impact: The divestiture may influence Glenmark's API production strategies, potentially affecting Atovaquone supply and export dynamics.
Common Questions — Atovaquone Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which atovaquone supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 58 recorded shipments worth $934.1M. GLENMARK PHARMACEUTICALS LIMITED (177 shipments) and HETERO LABS LIMITED (137 shipments) are also established high-volume exporters.
Q How many atovaquone manufacturers are there in India?
India has 17 active atovaquone exporters with a combined export market of $990.7M across 437 shipments to 21 countries. The top 5 suppliers hold 100.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for atovaquone from India?
Average FOB unit price: $40.71 per unit, ranging from $0.02 to $238.72. Average shipment value: $2.3M.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 17 verified Indian exporters of Atovaquone ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 437 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 21 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
437 Verified Shipments
17 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists